Company: VLDXW
Filing Date: 2025-08-07
Form Type: S-1
Source: 0001641172-25-022475
Chunk: 55

Company: Velo3D, Inc.
Filing Date: 2025-08-07
Form: S-1
Chunk 55
---
 To the extent shares are sold into the market by our stockholders pursuant to the Resale Shelf Registration
Statement, under Rule 144 under the Securities Act or otherwise, particularly in substantial quantities, the market price of our common
stock could decline.

| 35 |

In addition, we filed a shelf registration statement on Form S-3 (File No. 333-268346) on November 14, 2022, which permits us to sell from time-to-time up to $300.0 million of additional shares of our common stock or other securities in one or more offerings. In particular, we may offer and sell up to $75.0 million shares of our common stock from time to time pursuant to the ATM Sales Agreement that we have entered into with Needham. As of the filing date of this prospectus, we have sold approximately $24.6 million shares of our common stock pursuant to the ATM Sales Agreement.

On September 10, 2024, we received written notice from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist our common stock and publicly traded warrants and that trading in such securities would be suspended immediately. On September 11, 2024, the Company commenced the trading of its common stock and warrants on the OTCQX Best Market. As a result, we are not currently eligible to use Form S-3 or make sales under the ATM Sales Agreement as (i) our common stock is not currently listed on a national securities exchange registered under the Exchange Act; and (ii) the aggregate market value of our voting and non-voting common equity held by non-affiliates is below $75 million. If in the future we are again able to make sales under the ATM Sales Agreement, depending on market liquidity at the time, sales of our common stock pursuant to the ATM Sales Agreement, or other sales of our common stock or other securities under the shelf registration statement, may cause the trading price of our common stock to decline.

To the extent any of our outstanding warrants are exercised, it will increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.

As of July 31, 2025, we had 36,892 outstanding warrants to purchase an equal number of shares of common stock.

To the extent any of these warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and increase the